Corneal Cross-Linking (CXL) is a procedure to stop/slow the progression of Keratoconus, a degenerative eye disorder. Current procedures involve removing the epithelium (outer layer) of the cornea beforehand, which is painful, has slow recovery, and is risky. There are procedures to do this without removing the epithelium, but they are not yet FDA approved. Will they be?

Explanation of CXL: https://www.aao.org/eye-health/treatments/corneal-cross-linking-2

Current state of CXL research: https://www.reviewofophthalmology.com/article/the-epic-future-of-epion

Resolution criteria: official press release by the company developing this or a link to some official FDA resource indicating approval